-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Comparing Genfit (NASDAQ:GNFT) & Candel Therapeutics (NASDAQ:CADL)
Comparing Genfit (NASDAQ:GNFT) & Candel Therapeutics (NASDAQ:CADL)
Genfit (NASDAQ:GNFT – Get Rating) and Candel Therapeutics (NASDAQ:CADL – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.
Risk and Volatility
Genfit has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500.
Get Genfit alerts:Valuation and Earnings
This table compares Genfit and Candel Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Genfit | $101.25 million | 1.76 | $79.57 million | N/A | N/A |
Candel Therapeutics | $130,000.00 | 366.73 | -$36.12 million | ($0.42) | -3.93 |
Profitability
This table compares Genfit and Candel Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Genfit | N/A | N/A | N/A |
Candel Therapeutics | N/A | -20.18% | -13.13% |
Institutional and Insider Ownership
4.2% of Genfit shares are held by institutional investors. Comparatively, 22.0% of Candel Therapeutics shares are held by institutional investors. 44.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Genfit and Candel Therapeutics, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Genfit | 0 | 0 | 2 | 0 | 3.00 |
Candel Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
Genfit presently has a consensus target price of $9.00, indicating a potential upside of 152.10%. Candel Therapeutics has a consensus target price of $10.33, indicating a potential upside of 526.26%. Given Candel Therapeutics' higher possible upside, analysts plainly believe Candel Therapeutics is more favorable than Genfit.
About Genfit
(Get Rating)
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
About Candel Therapeutics
(Get Rating)
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
Genfit (NASDAQ:GNFT – Get Rating) and Candel Therapeutics (NASDAQ:CADL – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.
Genfit(纳斯达克:GNFT-GET评级)和Candel Treateutics(纳斯达克:CADL-GET评级)都是小盘股医疗公司,但哪只股票更好?我们将根据这两家公司的股息实力、分析师建议、收益、盈利能力、估值、机构所有权和风险对它们进行比较。
Risk and Volatility
风险和波动性
Genfit has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500.
Genfit的贝塔系数为1.41,表明其股价的波动性比标准普尔500指数高出41%。相比之下,Candel Treeutics的贝塔系数为0.18,这表明其股价的波动性比标准普尔500指数低82%。
Valuation and Earnings
估值和收益
This table compares Genfit and Candel Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
下表比较了Genfit和Candel治疗公司的营收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Genfit | $101.25 million | 1.76 | $79.57 million | N/A | N/A |
Candel Therapeutics | $130,000.00 | 366.73 | -$36.12 million | ($0.42) | -3.93 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
金菲特 | 1.0125亿美元 | 1.76 | 7957万美元 | 不适用 | 不适用 |
秋茄治疗公司 | $130,000.00 | 366.73 | -3,612万元 | ($0.42) | -3.93 |
Profitability
盈利能力
This table compares Genfit and Candel Therapeutics' net margins, return on equity and return on assets.
下表比较了Genfit和Candel治疗公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Genfit | N/A | N/A | N/A |
Candel Therapeutics | N/A | -20.18% | -13.13% |
净利润率 | 股本回报率 | 资产回报率 | |
金菲特 | 不适用 | 不适用 | 不适用 |
秋茄治疗公司 | 不适用 | -20.18% | -13.13% |
Institutional and Insider Ownership
机构和内部人持股
4.2% of Genfit shares are held by institutional investors. Comparatively, 22.0% of Candel Therapeutics shares are held by institutional investors. 44.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Genfit 4.2%的股份由机构投资者持有。相比之下,Candel Treateutics 22.0%的股份由机构投资者持有。坎德尔治疗公司44.3%的股份由内部人士持有。强大的机构持股表明,捐赠基金、对冲基金和大型基金管理公司相信,一家公司有望实现长期增长。
Analyst Recommendations
分析师建议
This is a breakdown of current ratings and target prices for Genfit and Candel Therapeutics, as provided by MarketBeat.com.
这是由MarketBeat.com提供的Genfit和Candel治疗公司的当前评级和目标价格的细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Genfit | 0 | 0 | 2 | 0 | 3.00 |
Candel Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
金菲特 | 0 | 0 | 2 | 0 | 3.00 |
秋茄治疗公司 | 0 | 0 | 3 | 0 | 3.00 |
Genfit presently has a consensus target price of $9.00, indicating a potential upside of 152.10%. Candel Therapeutics has a consensus target price of $10.33, indicating a potential upside of 526.26%. Given Candel Therapeutics' higher possible upside, analysts plainly believe Candel Therapeutics is more favorable than Genfit.
Genfit目前的普遍目标价为9美元,表明潜在上涨152.10%。Candel Treeutics的共识目标价为10.33美元,表明潜在上涨526.26%。考虑到Candel治疗公司更高的可能上行空间,分析师们显然认为Candel治疗公司比Genfit更有利。
About Genfit
关于Genfit
(Get Rating)
(获取评级)
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Genfit S.A.是一家生物制药公司,发现和开发代谢和肝脏相关疾病的候选药物和诊断解决方案。该公司的产品包括Elafibror,它正处于第三阶段临床试验,用于治疗原发性胆管炎患者。它还致力于NIS4技术的开发,用于诊断非酒精性脂肪性肝炎(NASH)和纤维化;GNS561,正处于1b/2期试验,用于治疗胆管癌(CCA);以及硝唑西尼,正处于1期试验,用于治疗急慢性肝功能衰竭。该公司与Labcorp签署了一项许可协议,将基于血液的分子诊断测试NASHNext商业化;并与Genoscience Pharma签署了一项协议,以开发用于CCA的研究治疗GNS561并将其商业化。Genfit S.A.成立于1999年,总部设在法国卢斯。
About Candel Therapeutics
关于秋茄治疗公司
(Get Rating)
(获取评级)
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Candel治疗公司是一家临床阶段的生物制药公司,致力于为癌症患者开发免疫疗法。该公司开发了CAN-2409,目前正处于治疗胰腺癌的第二阶段临床试验;治疗前列腺癌的第三阶段临床试验;以及治疗肺癌的第二阶段临床试验,以及治疗高级别胶质瘤的Ib/II阶段临床试验。它还开发了CAN-3110,这是一种治疗复发胶质母细胞瘤的I期临床试验。它还开发了启迪发现平台,这是一个系统的、基于HSV的迭代发现平台,利用人类生物学和先进的分析来为实体肿瘤创造新的病毒免疫疗法。该公司前身为Advantagene,Inc.,并于2020年11月更名为Candel治疗公司。该公司成立于2003年,总部设在马萨诸塞州的尼达姆。
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genfit日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genfit和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧